List of Excipients in Branded Drug CARISOPRODOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wallace Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	ALGINIC ACID
Wallace Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	MAGNESIUM STEARATE
Wallace Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	POTASSIUM SORBATE
Wallace Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	STARCH, CORN
Wallace Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	TRIBASIC CALCIUM PHOSPHATE

Generic Drugs Containing CARISOPRODOL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	METHYLCELLULOSE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	POVIDONE K30
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CARISOPRODOL?

# Of NDCs	Excipient
1	ALGINIC ACID
17	ANHYDROUS LACTOSE
100	CELLULOSE, MICROCRYSTALLINE
3	COLLOIDAL SILICON DIOXIDE
74	CROSCARMELLOSE SODIUM
8	CROSPOVIDONE

Excipient Strategy and Commercial Opportunities for Carisoprodol

Last updated: February 25, 2026

What is the current excipient profile for Carisoprodol?

Carisoprodol is a centrally acting muscle relaxant approved in the United States since 1959. Its formulations predominantly include the active ingredient with excipients designed to optimize stability, bioavailability, and shelf life. Typical excipients used in commercial formulations of Carisoprodol include:

• Microcrystalline cellulose: Disintegrant and binder.
• Lactose monohydrate: Diluent.
• Magnesium stearate: Lubricant.
• Starch: Disintegrant.

These excipients are standard, cost-effective, and generally recognized as safe (GRAS). The choice of excipients influences the drug's pharmacokinetics, stability, and patient tolerability.

How can excipient strategy enhance product performance?

Optimizing excipient composition can:

• Improve bioavailability: Incorporate excipients like surfactants or permeability enhancers.
• Extend shelf life: Use antioxidants or moisture scavengers.
• Reduce adverse effects: Select excipients with lower allergenic potential or gastrointestinal irritation.

For example, replacing lactose with non-dairy disintegrants may mitigate issues for lactose-intolerant patients. Using controlled-release excipients can modify pharmacokinetics, possibly expanding indications or dosing regimens.

What are emerging excipient technologies relevant to Carisoprodol?

Advancements include:

• Solubilizing excipients: Cyclodextrins can improve solubility of poorly water-soluble drugs.
• Novel polymers: For controlled-release matrices, like methacrylic acid copolymers.
• Mucoadhesive agents: Enhance local or systemic absorption.

Implementing these technologies can differentiate products, enable strategic licensing, or support development of new formulations such as quick-dissolving or sustained-release versions.

What are the commercial opportunities stemming from excipient innovation?

1. Formulation Differentiation: Creating formulations with improved onset, duration, or tolerability to capture niche markets or extend patent life.

2. Patent Extensions: Developing unique formulations with novel excipients could support new patent filings or exclusivity periods.

3. Lifecycle Management: Introducing alternative formulations for existing markets to address patient preferences or regulatory requirements.

4. Biosimilar and Generics: Enhancing stability and bioavailability profiles can streamline regulatory approval for lower-cost products.

How do regulatory considerations influence excipient selection?

Excipients must meet regulatory standards, with emphasis on:

• GRAS status (FDA or EMA)
• Compatibility with the active ingredient
• Patient safety (allergenicity, gastrointestinal safety)
• Labeling requirements

Innovations involving novel excipients require extensive safety and stability data, potentially increasing development time and cost.

What are the market dynamics and patent landscape?

• Dominant brands primarily use traditional excipients.
• Patent expiration of some formulations opens opportunities for reformulation with improved excipients.
• Regulatory pathways for novel excipients are more complex, impacting commercial viability.

The global muscle relaxant market was valued at USD 3.2 billion in 2021[1]. Carisoprodol's patent status influences the scope of innovation; new formulations using advanced excipients can capture market share amid generic competition.

What are key challenges and considerations?

• Ensuring excipient compatibility with active pharmacology.
• Managing variability in excipient quality across manufacturing sites.
• Navigating complex regulatory pathways for novel excipients.
• Balancing cost-effectiveness with formulation innovation.

Key Takeaways

• Standard excipients in Carisoprodol include microcrystalline cellulose and lactose.
• Innovation in excipients offers avenues for formulation differentiation, patent extension, and market expansion.
• Advanced excipient technologies such as controlled-release polymers and solubilizers can improve product performance.
• Regulatory compliance and safety remain top priorities when selecting excipients.
• Market competition and patent expirations motivate reformulation strategies leveraging excipient innovation.

FAQs

1. Can non-traditional excipients improve Carisoprodol formulations?
Yes, excipients like cyclodextrins or advanced polymers can enhance solubility, control release, or reduce side effects.

2. Are there regulatory hurdles to using novel excipients?
Yes, novel excipients require extensive safety and stability data, which can delay commercialization.

3. How does excipient choice impact patent strategies?
Novel excipients can support new patents or exclusivities through reformulation, extending product lifecycle.

4. What excipients are suitable for developing immediate-release versus sustained-release Carisoprodol?
Immediate-release formulations typically use disintegrants and fillers; sustained-release use controlled-release polymers and matrix formers.

5. What market factors influence investment in excipient technology for Carisoprodol?
Patent expirations, unmet patient needs, and formulation differentiation drive investment, especially in off-patent markets.

---

References

[1] MarketResearch.com. (2021). Musculoskeletal Drugs Market Analysis.